Website intended for a NZ health professional readership
This article looks at the New Zealand COVID-19 vaccine rollout strategy – where we are at and where we are going – as well as how safety and efficacy of COVID-19 vaccines are being monitored globally
1. Ahmad FB, Cisewski JA, Miniño A, et al. Provisional mortality data – United States, 2020. MMWR Morb Mortal Wkly Rep 2021;70(14):519–22.
2. Ritchie H, Ortis-Ospina E, Beltekian D, et al. Coronavirus (COVID-19) vaccinations. Our World In Data. ourworldindata.org/covid-vaccinations
3. Medsafe. Adverse events following immunisation with COVID-19 vaccines: Safety Report #4 – 27 March 2021. medsafe.govt.nz/COVID-19/vaccine-report-overview.asp
4. AusVaxSafety. COVID-19 vaccine safety surveillance. 25 April 2021. ausvaxsafety.org.au/safety-data/covid-19-vaccines
5. Thompson M, Burgess J, Naleway A, et al. Interim estimates of vaccine effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines in preventing SARS-CoV-2 infection among health care personnel, first responders, and other essential and frontline workers — eight U.S. locations, December 2020–March 2021. MMWR Morb Mortal Wkly Rep 2021;70(13):495–500.
6. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 2020;383(27):2603–15.
7. Pimenta D, Yates C, Pagel C, et al. Delaying the second dose of covid-19 vaccines BMJ 2021;372:n710.
8. Dagan N, Barda N, Kepten E, et al. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. N Engl J Med 2021;384(15):1412–23.
9. Bernal JL, Andrews N, Gower C, et al. Early effectiveness of COVID-19 vaccination with BNT162b2 mRNA vaccine and ChAdOx1 adenovirus vector vaccine on symptomatic disease, hospitalisations and mortality in older adults in England. medRxiv [preprint] 2021.03.01.21252652.
10. Pfizer-BioNTech announce positive topline results of pivotal COVID-19 vaccine study in adolescents. New York and Mainz: Business Wire; 31 March 2021. businesswire.com/news/home/20210331005503/en/
Pharmacist prescribers Linda Bryant and Leanne Te Karu discuss positive polypharmacy for heart failure. Current evidence shows the intensive implementation of four medications offers the greatest benefit to most patients with heart failure, with significant reductions in cardiovascular mortality, heart failure hospitalisations and all-cause mortality
